Pharming Group (PHAR) Financial Statements & Analysis

Pharming Group (PHAR) Income Statement

Pharming Group reported revenue of EUR 376.13M in fiscal 2025 (fiscal year ended Dec 31, 2025), up 26.6% from EUR 297.20M a year earlier. Net income was EUR 2.85M, a net margin of 0.8%. Gross margin was 87.9% and operating margin 5.6%. In the most recent quarter, Q2 fiscal 2026 (ended Jun 30, 2026), revenue was $90.21M, down 3.2% from the same quarter a year earlier.

Pharming Group Income Statement Analysis

Values in millions EUR

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Pharming Group N.V. income statement - Annual data in millions EUR
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017
Revenue & Gross Profit
Revenue	376.13	297.20	245.32	205.62	198.87	212.17	189.39	154.58	107.52
Cost of Revenue	45.50	35.40	25.21	17.56	21.14	23.54	23.93	25.37	14.93
Gross Profit	330.63	261.80	220.10	188.06	177.73	188.64	165.46	129.20	92.59
Operating Expenses
Research & Development	100.37	83.15	68.91	52.53	65.38	38.52	31.79	33.04	22.38
Selling, General & Administrative	117.44	99.22	87.50	68.85	90.97	65.00	55.88	46.84	44.86
Operating Expenses	309.75	265.47	242.39	178.20	330.96	112.38	97.22	85.74	66.30
Operating Income	20.88	-3.67	-22.29	9.86	13.56	76.26	68.25	43.46	26.29
Other Income/Expense
Interest Income	2.18	5.92	3.66	0.09	0.69	0.71	1.13	0.02	0.00
Interest Expense	10.72	9.05	5.96	5.36	-6.09	10.31	13.35	16.37	45.41
Other Income/Expense	-8.03	-4.83	12.71	5.13	9.52	-32.16	-15.94	-42.48	-129.09
Income
Income Before Tax	12.85	-8.49	-12.01	14.99	23.08	44.09	52.30	0.98	-102.80
Income Tax Expense	10.31	3.35	-1.46	1.31	-7.08	6.35	11.75	-27.61	-11.33
Net Income	2.85	-11.84	-10.55	13.67	16.00	37.75	40.56	28.59	-91.47
Net Income - Continuous Operations	2.85	-11.84	-10.55	13.67	16.00	37.75	40.56	28.59	-91.47
Net Income - Discontinued Operations	-	-	-	-	-	-	-	-	-
EBITDA	34.78	16.32	9.88	33.53	30.39	58.35	71.46	24.85	-76.33
EBIT	23.57	-3.59	-6.05	20.35	24.00	76.26	-	-	-
Depreciation & Amortization	11.22	16.07	9.16	13.19	6.39	8.31	5.80	7.50	4.10
Earnings Per Share
Basic EPS	-	-	-	-	-	-	1.00	-	-1.00
Diluted EPS	-	-	-	-	-	-	-	-	-1.00
Basic Shares Outstanding	71.32	68.92	67.46	82.54	642.01	79.88	84.19	81.69	62.55
Diluted Shares Outstanding	71.32	68.92	67.46	84.28	701.15	80.98	84.19	81.69	62.55

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Pharming Group Financial Statements

What was Pharming Group's revenue in fiscal 2025?

Pharming Group reported revenue of EUR 376.13M in fiscal 2025 (fiscal year ended Dec 31, 2025). That was up 26.6% from EUR 297.20M a year earlier.

Is Pharming Group profitable?

Yes. Pharming Group earned net income of EUR 2.85M in fiscal 2025, a net margin of 0.8%. In fiscal 2024 it lost EUR 11.84M.

What is Pharming Group's operating margin?

Pharming Group's operating income was EUR 20.88M on revenue of EUR 376.13M in fiscal 2025, an operating margin of 5.6%, compared with -1.2% a year earlier.

What is net profit margin?

Net profit margin is net income divided by revenue. It shows how much of each dollar of sales a company keeps as profit after all costs, interest and taxes. Full definition